161 completed, 66 recruiting, 54 terminated, 36 unknown. 376 Phase 1, 134 Phase 2.
Follow Uterine Cervical Neoplasms: new trials by email Literature Review of Uterine Cervical Neoplasms trials Research Report on Uterine Cervical Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| COQ10 and Vitamin E for Off-Target Radiation Toxicity Coenzyme Q10 Cap/Tab, Vitamin E Cap/Tab - Prostate Cancer, Uterine Cancer | Phase 1 / Phase 2 | Not yet recruiting | University of Nebraska | 200 | 2026-12-01 | 2026-10-08 |
| A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors ARV-6723, Pembrolizumab, SOC - Advanced Solid Tumor | Phase 1 / Phase 2 | Recruiting | Arvinas Inc. | 499 | 2026-07-29 | 2026-10-13 |
| Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors RGT-490 - Breast Cancer, Ovarian Cancer | Phase 1 | Recruiting | Regor Pharmaceuticals Inc. | 63 | 2026-07-21 | 2026-11-02 |
| A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors HH160 - Solid Tumor, Non-small Cell Lung Cancer | Phase 1 | Recruiting | Huahui Health | 299 | 2026-06-11 | 2026-08-21 |
| Engineered Immune Effectors Against Cervical Cancer CC-EIEs - Cervical Cancer | Phase 1 / Phase 2 | Terminated | Shenzhen Geno-Immune Medical Institute | 20 | 2026-06-01 | 2026-11-03 |
| Intervention of CAR-T Against Cervical Cancer Cervical cancer-specific CAR-T cells - Cervical Cancer | Phase 1 / Phase 2 | Terminated | Shenzhen Geno-Immune Medical Institute | 20 | 2026-06-01 | 2026-11-03 |
| ASCERV Study: MRG003 Combined With QL1706 in Recurrent or Metastatic Cervical Cancer Treatment - Recurrent or Metastatic Cervical Cancer | Phase 1 / Phase 2 | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 41 | 2026-04-10 | 2026-04-21 |
| A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01 KRC-01, External Beam Radiation Therapy, cisplatin - Cervical Cancer | Phase 1 | Recruiting | Kortuc, Inc. | 70 | 2026-03-01 | 2026-04-08 |
| 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors 177Lu-BetaBart, BetaBart + unlabeled BetaBart - Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer | Phase 1 / Phase 2 | Recruiting | Radiopharm Theranostics, Ltd | 61 | 2026-02-23 | 2026-10-01 |
| Hyaluronic Acid-based Gel Spacers in Gynecologic Malignancies Barrigel gel spacer - Cervix Cancer | Phase 1 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 14 | 2026-02-02 | 2026-10-01 |
| Neoadjuvant Lymph Node Targeted Immunotherapy in Cervical Cancer: a Feasibility Study (NEOLYNC) Nivolumab - Cervical Carcinoma | Phase 1 | Recruiting | University Medical Center Groningen | 12 | 2026-01-05 | 2026-06-17 |
| STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma Aldesleukin, Biopsy, Biospecimen Collection - Locally Advanced Cervical Carcinoma, Locally Advanced Colorectal Carcinoma | Phase 1 | Withdrawn | City of Hope Medical Center | 2025-12-05 | 2025-12-24 | |
| A Multiple Tumor Species, Open and Multi-center Clinical Study of Alpaloritovorelli Antibodies (QL-1706) Combined with Pulsed Low Dose Rate External Irradiation (PLDR) for Disease Progression After Previous Anti-tumor Therapy Pulsed low dose rate radiotherapy (PLDR), Alpaloritovorelli antibodies - Esophageal Cancer, Non Small Cell Lung Cancer | Phase 1 | Not yet recruiting | Anhui Provincial Hospital | 90 | 2025-12-01 | 2025-01-07 |
| Alendronate to Reduce Pelvic Insufficiency Fractures in Cervical Cancer Patients Undergoing Chemoradiation Alendronate 70mg weekly - Cervix Cancer | Phase 1 / Phase 2 | Not yet recruiting | Dr. Itay GoorAryeh | 65 | 2025-12-01 | 2025-11-24 |
| A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4 RNDO-564, Pembrolizumab - Non Small Cell Lung Cancer, Cervical Cancer | Phase 1 | Enrolling by invitation | Rondo Therapeutics | 149 | 2025-11-17 | 2026-06-11 |
| A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors KIVU-107 - Advance Solid Tumors | Phase 1 | Recruiting | Kivu Bioscience Inc. | 76 | 2025-11-13 | 2026-09-24 |
| Study of TI-0093 Injection With Recurrent/Metastatic HPV-16 Positive Solid Tumors therapeutic tumor vaccine - HPV 16+ Recurrent or Metastatic Cancer, HNSCC | Phase 1 | Recruiting | Therorna | 12 | 2025-11-11 | 2025-11-24 |
| A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer STRO-004, Pembrolizumab - Head and Neck Squamous Cell Carcinoma HNSCC, Non-Small Cell Lung Cancer NSCLC | Phase 1 | Recruiting | Sutro Biopharma, Inc. | 200 | 2025-11-07 | 2026-08-27 |
| A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors NRM-823 - HNSCC, ESCC | Phase 1 | Recruiting | Normunity AccelCo, Inc. | 150 | 2025-10-30 | 2026-08-18 |
| AssociatiNG Bevacizumab bEmarituzumab for GynecoLogIcal CAncer Bemarituzumab, Bevacizumab - Endometrial Carcinoma, Ovarian Cancer | Phase 1 / Phase 2 | Withdrawn | Centre Leon Berard | 2025-10-15 | 2026-04-23 |
Showing 20 of 376. Sign in to see all of them.
Ovarian Neoplasms (120) · Carcinoma, Non-Small-Cell Lung (104) · Endometrial Neoplasms (103) · Squamous Cell Carcinoma of Head and Neck (81) · Stomach Neoplasms (78) · Breast Neoplasms (71) · Melanoma (69) · Esophageal Neoplasms (68) · Carcinoma, Renal Cell (65) · Triple Negative Breast Neoplasms (58) · Colorectal Neoplasms (56) · Pancreatic Neoplasms (55) · Urinary Bladder Neoplasms (52) · Neoplasms (51)
Female Urogenital Diseases (376) · Female Urogenital Diseases and Pregnancy Complications (376) · Genital Diseases (376) · Urogenital Diseases (376) · Genital Diseases, Female (375) · Uterine Cervical Diseases (375) · Uterine Diseases (375) · Urogenital Neoplasms (371) · Genital Neoplasms, Female (370) · Neoplasms by Site (368) · Uterine Neoplasms (358) · Neoplasms (325) · Neoplasms by Histologic Type (183) · Neoplasms, Glandular and Epithelial (165) · Digestive System Diseases (159)
pembrolizumab (42) · Cisplatin (38) · Brachytherapy (20) · Carboplatin (20) · Radiotherapy (19) · Paclitaxel (14) · Cyclophosphamide (13) · Bevacizumab (12) · Nivolumab (11) · fludarabine (11) · Radiation (10) · Topotecan (10) · Docetaxel (8) · aldesleukin (8) · 1,2-diaminocyclohexaneplatinum II citrate (7)
National Cancer Institute (NCI) (26) · Gynecologic Oncology Group (6) · Chongqing Precision Biotech Co., Ltd (5) · Eli Lilly and Company (5) · M.D. Anderson Cancer Center (5) · Seagen Inc. (5) · University Health Network, Toronto (5) · Incyte Biosciences International Sàrl (4) · Incyte Corporation (4) · Peking Union Medical College Hospital (4) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (4) · UNC Lineberger Comprehensive Cancer Center (4) · Washington University School of Medicine (4) · AstraZeneca (3) · Cancer Research UK (3)
United States (230) · China (69) · Spain (39) · Australia (38) · Canada (36) · United Kingdom (33) · France (32) · South Korea (27) · Belgium (20) · Japan (20) · Italy (18) · Netherlands (16) · Taiwan (13) · Germany (10) · Poland (9)
Anthony Fyles, MD (3) · Steven A Rosenberg, M.D. (3) · Charalampos Floudas, M.D. (2) · Chemtai Mungo, MD, MPH, FACOG (2) · Christian S Hinrichs, M.D. (2) · Christian S Hinrichs, MD (2) · Cornelia L. Trimble, MD (2) · Fuquan Zhang, M.D. (2) · Jason Wu (2) · Javier Morales, MD (2) · Jeremie Calais (2)
PMID 19949018, PMID 22002018, PMID 37496366, PMID 41044356, PMID 42580817, PMID 15863167, PMID 16597660, PMID 16889823, PMID 17084549, PMID 17398031, PMID 17482376, PMID 17910981, PMID 18299147, PMID 19010522, PMID 19118066, PMID 19238149, PMID 19509178, PMID 19671873, PMID 20068553, PMID 20179219, PMID 20347480, PMID 21892091, PMID 23385153, PMID 23731770, PMID 24161937, PMID 24477000, PMID 24576907, PMID 24731816, PMID 25802932, PMID 25915780, PMID 25944802, PMID 26106073, PMID 26176261, PMID 26420854, PMID 26541586, PMID 27016411, PMID 27998970, PMID 28291390, PMID 28548889, PMID 28558150, PMID 28679770, PMID 28744123, PMID 29066505, PMID 29186019, PMID 29252124, PMID 30091600, PMID 30184767, PMID 30603797, PMID 30715452, PMID 30745090
2023 (11), U10CA027469 (7), 2019 (6), U10CA180868 (4), 2014 (3), 2016 (3), 2009 (2), 2015 (2), 2017 (2), 2018 (2), P30CA043703 (2), P50CA098252 (2), K12HD103085 (1), P30CA006973 (1), P30CA016087 (1)